BNP Paribas Financial Markets Has $14.89 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BNP Paribas Financial Markets boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 22.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,425,984 shares of the company's stock after acquiring an additional 265,410 shares during the period. BNP Paribas Financial Markets owned about 0.13% of Teva Pharmaceutical Industries worth $14,887,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TEVA. Bank of New York Mellon Corp grew its holdings in Teva Pharmaceutical Industries by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 1,902,235 shares of the company's stock valued at $19,403,000 after purchasing an additional 19,906 shares during the period. Advisor Partners II LLC grew its stake in shares of Teva Pharmaceutical Industries by 62.5% during the 3rd quarter. Advisor Partners II LLC now owns 25,359 shares of the company's stock valued at $259,000 after buying an additional 9,757 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $164,000. Teacher Retirement System of Texas raised its position in shares of Teva Pharmaceutical Industries by 6.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 388,338 shares of the company's stock worth $3,961,000 after buying an additional 22,893 shares during the period. Finally, Bourgeon Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 1.5% in the third quarter. Bourgeon Capital Management LLC now owns 661,613 shares of the company's stock valued at $6,748,000 after acquiring an additional 9,853 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 2.9 %

TEVA traded down $0.48 on Thursday, reaching $16.30. The company's stock had a trading volume of 16,157,617 shares, compared to its average volume of 11,087,646. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 1 year low of $7.09 and a 1 year high of $17.13. The business's 50 day moving average is $14.01 and its 200 day moving average is $12.01. The stock has a market cap of $18.27 billion, a price-to-earnings ratio of -39.76, a price-to-earnings-growth ratio of 2.02 and a beta of 1.04.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now owns 1 shares of the company's stock, valued at $13.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of the firm's stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 299,661 shares of company stock valued at $4,014,517. 0.55% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. The Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a report on Monday, February 5th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a research note on Friday, March 8th. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday. Finally, Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and raised their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $14.22.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.